Xenon Pharmaceuticals (XENE) Amortization of Deferred Charges (2024 - 2026)

Xenon Pharmaceuticals (XENE) has 3 years of Amortization of Deferred Charges data on file, last reported at $338000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 4.97% year-over-year to $338000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 4.89% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 4.7% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $338000.0, up from $334000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for XENE reached as high as $338000.0 in Q1 2026 and fell as low as $309000.0 in Q1 2024.
• Historically, Amortization of Deferred Charges has averaged $322777.8 across 3 years, with a median of $322000.0 in 2025.
• On a YoY basis, Amortization of Deferred Charges climbed as much as 5.14% in 2025 and fell as far as 4.21% in 2025.
• Year by year, Amortization of Deferred Charges stood at $319000.0 in 2024, then gained by 4.7% to $334000.0 in 2025, then gained by 1.2% to $338000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $338000.0 in Q1 2026, $334000.0 in Q4 2025, and $330000.0 in Q3 2025.